BeiGene, Ltd.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
07725L102
SEDOL
BYYWPW6
CIK
0001651308
www.beigene.com
LEI:
©
FIGI: BBG00B6WF7T5
BGNE
BeiGene, Ltd.
GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology
AI
PROFILER
NAME
BeiGene, Ltd.
ISIN
US07725L1026
TICKER
BGNE
MIC
XNAS
REUTERS
BGNE.OQ
BLOOMBERG
BGNE US
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Fri, 13.12.2024       BeiGene
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (“CSPC”) for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhi...
Read More
BeiGene
Technical Analysis Termsheet Terminal
Permalink
Tue, 10.12.2024       BeiGene
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne Medicines Ltd., today announced the presentation of new clinical data at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, underscoring its leadership in chronic lymphocytic leukemia/small lymphocytic ...
Read More
BeiGene
Technical Analysis Termsheet Terminal
Permalink
Wed, 04.12.2024       BeiGene
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced its new partnership with CLL Society, the world’s leading authority for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) cancer patients. Together, they are advancing Test...
Read More
BeiGene
Technical Analysis Termsheet Terminal
Permalink
Mon, 02.12.2024       BeiGene
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will host an investor webcast on December 16, 2024 at 8:30 am EST. The Company’s R&D leadership team will provide an update on BeiGene’s innovative portfolio and pipeline, focusing on key...
Read More
BeiGene
Technical Analysis Termsheet Terminal
Permalink
Wed, 27.11.2024       BeiGene
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines, today announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma (ESCC) and gastric or gastroesop...
Read More
BeiGene
Technical Analysis Termsheet Terminal
Permalink
Tue, 26.11.2024       BeiGene
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will participate in fireside chats at two upcoming investor conferences: Citizens JMP Hematology and Oncology Summit on Monday, December 2 at 1:00 p.m. ET; and Citi’s Global Healthcare ...
Read More
BeiGene
Technical Analysis Termsheet Terminal
Permalink
Tue, 19.11.2024       BeiGene
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company which intends to change its name to BeOne Medicines Ltd., today announced it has entered into a settlement agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. resolving patent litigation related to MSN’s Abbreviated New Drug Application (ANDA) ...
Read More
BeiGene
Technical Analysis Termsheet Terminal
Permalink
Thu, 14.11.2024       BeiGene
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced its intent to change the Company’s name to BeOne Medicines Ltd., confirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible. This press release features...
Read More
BeiGene
Technical Analysis Termsheet Terminal
Permalink
Tue, 12.11.2024       BeiGene
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241112799807/en/(Graphic: Business Wire) “Our exceptional third-quar...
Read More
BeiGene
Technical Analysis Termsheet Terminal
Permalink
Wed, 06.11.2024       BeiGene
US07725L1026

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies London Healthcare Conference on November 20, 2024, with a fireside chat at 2:30 p.m. GMT. The live webcast of this event can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com, h...
Read More
BeiGene
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S